The 2022 top 100 bio­phar­ma in­vestors: A look back on boom times

RA Cap­i­tal dom­i­nat­ed the crossover game in 2021, run­ning the ta­ble as a host of biotechs an­gled for a quick leap on­to the pub­lic mar­ket. The RA crew, head­ed by Pe­ter Kolchin­sky and Raj Shah, even beat out Or­biMed last year on the to­tal num­ber of new deals ex­e­cut­ed, with both rep­re­sent­ing big spikes over 2020 deal lev­els.

Or­biMed, though, was in­volved with a larg­er amount of cash go­ing in­to new deals, typ­i­cal for the heavy­weight play­er in this in­dus­try. And if you ex­plore the charts be­low the top 100, you’ll see how the rush to the mar­ket helped tilt the scales to­ward ear­li­er stage biotechs.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN